Replimune (REPL) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $11.75, +3.16% vs the prior close of $11.39.
- Volume 1.61M shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
REPL jumps 3.2% to $11.75. Closed at $11.75, +3.16% vs the prior close of $11.39. Day range $11.23–$11.86, opened at $11.32.
REPL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — REPL jumps 3.2% to $11.75
- Closed at $11.75, +3.16% vs the prior close of $11.39. Day range $11.23–$11.86, opened at $11.32.
- Volume was 1.61M shares, 0.6x its 50-day average of 2.80M — lighter than usual.
- Price is -14.9% vs its 50-day average ($13.81) and +30.0% vs its 200-day average ($9.04).
- 52-week range $1.50–$16.33; today's close sits at 69% of that range, 28.0% below the 52-week high.
Oct 14, 2026 — REPL slides 5.9% to $11.39, a 1-month low, 3 down days in a row
- Closed at $11.39, -5.95% vs the prior close of $12.11. Day range $11.37–$12.37, opened at $12.05.
- Volume was 1.86M shares, 0.6x its 50-day average of 2.88M.
- Price is -17.5% vs its 50-day average ($13.81) and +26.1% vs its 200-day average ($9.03).
- 52-week range $1.50–$16.33; today's close sits at 67% of that range, 30.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — REPL slides 7.3% to $12.11, a 1-month low
- Closed at $12.11, -7.35% vs the prior close of $13.07. Day range $12.07–$12.93, opened at $12.91.
- Volume was 1.63M shares, 0.5x its 50-day average of 3.09M — lighter than usual.
- Price is -12.4% vs its 50-day average ($13.82) and +34.2% vs its 200-day average ($9.02).
- 52-week range $1.50–$16.33; today's close sits at 72% of that range, 25.8% below the 52-week high.
Oct 12, 2026 — REPL dips 2.6% to $13.07
- Closed at $13.07, -2.61% vs the prior close of $13.42. Day range $12.97–$13.56, opened at $13.21.
- Volume was 1.16M shares, 0.3x its 50-day average of 3.74M — lighter than usual.
- Price is -5.4% vs its 50-day average ($13.82) and +45.0% vs its 200-day average ($9.01).
- 52-week range $1.50–$16.33; today's close sits at 78% of that range, 20.0% below the 52-week high.
Oct 9, 2026 — REPL rises 2.9% to $13.42
- Closed at $13.42, +2.91% vs the prior close of $13.04. Day range $12.79–$13.44, opened at $12.96.
- Volume was 2.02M shares, 0.5x its 50-day average of 3.70M — lighter than usual.
- Price is -2.6% vs its 50-day average ($13.78) and +49.2% vs its 200-day average ($9.00).
- 52-week range $1.50–$16.33; today's close sits at 80% of that range, 17.8% below the 52-week high.
Oct 8, 2026 — REPL dips 1.2% to $13.04
- Closed at $13.04, -1.21% vs the prior close of $13.20. Day range $12.85–$13.46, opened at $13.18.
- Volume was 1.75M shares, 0.4x its 50-day average of 3.95M — lighter than usual.
- Price is -4.3% vs its 50-day average ($13.62) and +45.2% vs its 200-day average ($8.98).
- 52-week range $1.50–$16.33; today's close sits at 78% of that range, 20.1% below the 52-week high.
Oct 7, 2026 — REPL dips 0.4% to $13.20
- Closed at $13.20, -0.38% vs the prior close of $13.25. Day range $13.01–$13.60, opened at $13.14.
- Volume was 1.65M shares, 0.4x its 50-day average of 4.39M — lighter than usual.
- Price is -2.0% vs its 50-day average ($13.47) and +47.3% vs its 200-day average ($8.96).
- 52-week range $1.50–$16.33; today's close sits at 79% of that range, 19.2% below the 52-week high.
Oct 6, 2026 — REPL rises 0.8% to $13.25
- Closed at $13.25, +0.76% vs the prior close of $13.15. Day range $12.87–$13.51, opened at $13.17.
- Volume was 2.62M shares, 0.6x its 50-day average of 4.51M — lighter than usual.
- Price is -0.5% vs its 50-day average ($13.31) and +48.1% vs its 200-day average ($8.95).
- 52-week range $1.50–$16.33; today's close sits at 79% of that range, 18.9% below the 52-week high.
Oct 5, 2026 — REPL rises 0.6% to $13.15
- Closed at $13.15, +0.61% vs the prior close of $13.07. Day range $12.51–$13.29, opened at $13.14.
- Volume was 2.28M shares, 0.5x its 50-day average of 4.53M — lighter than usual.
- Price is -0.5% vs its 50-day average ($13.22) and +47.3% vs its 200-day average ($8.93).
- 52-week range $1.50–$16.33; today's close sits at 79% of that range, 19.5% below the 52-week high.
Oct 2, 2026 — REPL dips 2.8% to $13.07
- Closed at $13.07, -2.83% vs the prior close of $13.45. Day range $12.80–$13.83, opened at $13.69.
- Volume was 1.30M shares, 0.3x its 50-day average of 4.58M — lighter than usual.
- Price is -0.6% vs its 50-day average ($13.15) and +46.7% vs its 200-day average ($8.91).
- 52-week range $1.50–$16.33; today's close sits at 78% of that range, 20.0% below the 52-week high.
REPL latest news & SEC filings
Every SEC filing by or about REPL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 5.07 — Reported shareholder vote results.
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hill Emily Luisa sold 9,256 shares at $14.28 (≈$132.18K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form S-3ASR — S-3ASR filing
S-3ASR filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$69.77M (prior year -$86.69M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.72 (prior year -$0.95) (loss narrowed vs Jun 30, 2025)
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Patel Sushil sold 39,341 shares at $12.97 (≈$510.25K) on Aug 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hill Emily Luisa sold 11,448 shares at $12.97 (≈$148.48K) on Aug 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Xynos Konstantinos sold 11,447 shares at $12.97 (≈$148.47K) on Aug 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Schwendenman Andrew sold 7,632 shares at $12.97 (≈$98.99K) on Aug 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 11, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 8.01 — Reported other events the company considers important.
Aug 10, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade REPL
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: Jun 29, 2026, Feb 3, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.63% (largest 7.3%).
- Liquidity: about 2.05M shares (≈$24.13M) trade per day on average.
- 52-week position: $11.75 vs a range of $1.50–$16.33 (69% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 17 sales; latest: Emily Luisa Hill sold 9,256 shares on Aug 17, 2026.
- Latest filings: 8-K Sep 16, 2026; 10-Q Aug 14, 2026; 8-K Aug 14, 2026.
- Share count: 94.22M shares outstanding (Aug 11, 2026), +20.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
REPL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 11.32 | 11.86 | 11.23 | 11.75 | 1.61M |
| Oct 14, 2026 | 12.05 | 12.37 | 11.37 | 11.39 | 1.86M |
| Oct 13, 2026 | 12.91 | 12.93 | 12.07 | 12.11 | 1.63M |
| Oct 12, 2026 | 13.21 | 13.56 | 12.97 | 13.07 | 1.16M |
| Oct 9, 2026 | 12.96 | 13.44 | 12.79 | 13.42 | 2.02M |
| Oct 8, 2026 | 13.18 | 13.46 | 12.85 | 13.04 | 1.75M |
| Oct 7, 2026 | 13.14 | 13.60 | 13.01 | 13.20 | 1.65M |
| Oct 6, 2026 | 13.17 | 13.51 | 12.87 | 13.25 | 2.62M |
| Oct 5, 2026 | 13.14 | 13.29 | 12.51 | 13.15 | 2.28M |
| Oct 2, 2026 | 13.69 | 13.83 | 12.80 | 13.07 | 1.30M |
| Oct 1, 2026 | 13.26 | 13.59 | 13.06 | 13.45 | 2.52M |
| Sep 30, 2026 | 12.99 | 13.66 | 12.65 | 13.24 | 3.08M |
| Sep 29, 2026 | 12.44 | 13.42 | 12.35 | 13.00 | 4.37M |
| Sep 28, 2026 | 12.15 | 12.76 | 12.07 | 12.56 | 1.97M |
| Sep 25, 2026 | 12.63 | 12.80 | 12.30 | 12.36 | 1.65M |
| Sep 24, 2026 | 12.87 | 12.88 | 12.07 | 12.60 | 2.58M |
| Sep 23, 2026 | 13.50 | 13.60 | 12.68 | 12.96 | 1.89M |
| Sep 22, 2026 | 12.93 | 13.64 | 12.80 | 13.47 | 1.53M |
| Sep 21, 2026 | 13.11 | 13.28 | 12.76 | 12.87 | 1.46M |
| Sep 18, 2026 | 13.02 | 13.20 | 12.68 | 13.07 | 2.15M |
About Replimune
Replimune (REPL) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in WOBURN, MA. State of incorporation: DE. Fiscal year ends March 31. SEC CIK 1737953.
REPL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| L.P. 667, | Director | Aug 11, 2026 |
| Philip Astley-Sparke | Director | Aug 24, 2026 |
| Bros. Advisors Lp Baker | Director | Aug 11, 2026 |
| Felix Baker | Director | Aug 11, 2026 |
| Julian Baker | Director | Aug 11, 2026 |
| Bros. Advisors (Gp) Llc Baker | Director | Aug 11, 2026 |
| Brothers Life Sciences Lp Baker | Director | Aug 11, 2026 |
| Madhavan Balachandran | Director | Apr 7, 2026 |
| Kapil Dhingra | Director | Apr 7, 2026 |
| Christy J. Oliger | Director | Apr 7, 2026 |
| Sushil Patel | Chief Executive Officer | Aug 12, 2026 |
| Veleka Peeples-Dyer | Director | Apr 7, 2026 |
| Paolo Pucci | Director | Apr 7, 2026 |
| Joseph P Slattery | Director | Apr 7, 2026 |
| Dieter Weinand | Director | Apr 7, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Emily Luisa Hill | Chief Financial Officer | Aug 19, 2026 |
| Sushil Patel | Chief Executive Officer | Aug 12, 2026 |
| Christopher Sarchi | Chief Commercial Officer | Jun 3, 2026 |
| Andrew Schwendenman | Chief Accounting Officer | Aug 12, 2026 |
| Konstantinos Xynos | Chief Medical Officer | Aug 12, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 17, 2026 | Emily Luisa Hill | Sale | 9,256 | $14.28 |
| Aug 10, 2026 | Konstantinos Xynos | Sale | 11,447 | $12.97 |
| Aug 10, 2026 | Andrew Schwendenman | Sale | 7,632 | $12.97 |
| Aug 10, 2026 | Sushil Patel | Sale | 39,341 | $12.97 |
| Aug 10, 2026 | Emily Luisa Hill | Sale | 11,448 | $12.97 |
| Jun 1, 2026 | Christopher Sarchi | Sale | 12,000 | $9.24 |
| May 18, 2026 | Konstantinos Xynos | Sale | 14,023 | $5.08 |
| May 18, 2026 | Andrew Schwendenman | Sale | 7,894 | $5.08 |
| May 18, 2026 | Emily Luisa Hill | Sale | 7,812 | $5.08 |
| May 18, 2026 | Christopher Sarchi | Sale | 8,626 | $5.08 |
| May 18, 2026 | Sushil Patel | Sale | 37,324 | $5.08 |
| May 18, 2026 | Philip Astley-Sparke | Sale | 17,657 | $5.08 |
| Apr 2, 2026 | Christopher Sarchi | Sale | 6,500 | $8.01 |
| Dec 9, 2025 | Kapil Dhingra | Sale | 3,169 | $10.40 |
| Dec 2, 2025 | Sushil Patel | Sale | 10,000 | $11.13 |
REPL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Mar 31, 2026 | — | $-313.94M | -3.38 | $-280.34M |
| Mar 31, 2025 | — | $-247.30M | -3.07 | $-192.25M |
| Mar 31, 2024 | — | $-215.79M | -3.24 | $-185.47M |
| Mar 31, 2023 | — | $-174.28M | -2.99 | $-128.05M |
| Mar 31, 2022 | — | $-118.04M | -2.26 | $-82.18M |
Latest balance sheet: total assets $252.45M, total liabilities $146.80M, cash $185.36M (as of Jun 30, 2026).
REPL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $14.97 |
| Jun 29, 2026 | 8-K Item 2.02 (results) | $11.20 |
| Feb 3, 2026 | 8-K Item 2.02 (results) | $7.38 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $8.50 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $5.48 |
| May 22, 2025 | 8-K Item 2.02 (results) | $8.76 |
| Feb 12, 2025 | 8-K Item 2.02 (results) | $13.79 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $12.19 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 16, 2024 | 8-K Item 2.02 (results) | — |
| Feb 8, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on REPL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.